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Background: The level of plasma-derived naturally circulating anti-glycan antibodies (AGA) to P1 trisaccharide has previously been
shown to significantly discriminate between ovarian cancer patients and healthy women. Here we aim to identify the Ig class that
causes this discrimination, to identify on cancer cells the corresponding P1 antigen recognised by circulating anti-P1 antibodies
and to shed light into the possible function of this glycosphingolipid.
Methods: An independent Australian cohort was assessed for the presence of anti-P1 IgG and IgM class antibodies using
suspension array. Monoclonal and human derived anti-glycan antibodies were verified using three independent glycan-based
immunoassays and flow cytometry-based inhibition assay. The P1 antigen was detected by LC-MS/MS and flow cytometry. FACS-
sorted cell lines were studied on the cellular migration by colorimetric assay and real-time measurement using xCELLigence
system.
Results: Here we show in a second independent cohort (n¼ 155) that the discrimination of cancer patients is mediated by the IgM
class of anti-P1 antibodies (P¼ 0.0002). The presence of corresponding antigen P1 and structurally related epitopes in fresh tissue
specimens and cultured cancer cells is demonstrated. We further link the antibody and antigen (P1) by showing that human
naturally circulating and affinity-purified anti-P1 IgM isolated from patients ascites can bind to naturally expressed P1 on the cell
surface of ovarian cancer cells. Cell-sorted IGROV1 was used to obtain two study subpopulations (P1-high, 66.1%; and P1-low,
33.3%) and observed that cells expressing high P1-levels migrate significantly faster than those with low P1-levels.
Conclusions: This is the first report showing that P1 antigen, known to be expressed on erythrocytes only, is also present on
ovarian cancer cells. This suggests that P1 is a novel tumour-associated carbohydrate antigen recognised by the immune system in
patients and may have a role in cell migration. The clinical value of our data may be both diagnostic and prognostic; patients with
low anti-P1 IgM antibodies present with a more aggressive phenotype and earlier relapse.
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Glycosphingolipids (GSLs) have critical roles in embryonic
development, signal transduction, cell signalling, apoptosis,
receptor modulation, cell adhesion, growth and cell differentiation
and carcinogenesis (Jarvis et al, 1996; Hakomori, 1998; Kasahara
and Sanai, 1999). The presence of tumour-associated GSLs
antigens have been observed in epithelial ovarian cancer
(Pochechueva et al, 2012), which is the fifth most common cause
of death from all cancers in women and the leading cause of death
from gynaecological malignancies (Ozols, 2006).
Printed glycan array technology (a glycan-based discovery
approach) previously demonstrated that naturally occurring anti-
glycan antibodies (AGA) in plasma of ovarian cancer patients
exhibited specificities towards synthetic P1 trisaccharide. In our
previous study, we have demonstrated using a printed glycan array
that anti-P1 antibodies can discriminate healthy controls from
ovarian cancer patients (Jacob et al, 2012). This study (on a Swiss
Discovery Cohort) showed that anti-P1 antibodies of IgM, IgG and
IgA together were significantly lower in ovarian cancer patients,
thereby discriminating them from healthy controls. The predictive
value of the printed glycan array was validated by two independent
glycan-based immunoassays, ELISA and suspension array
(Pochechueva et al, 2011b).
The Pk, P and P1 carbohydrate antigens, commonly expressed
on GSL, are members of the P blood group system that differ in
their specificity based on their oligosaccharide sequences. In
cancer, the globo (Pk and P) and neolacto (P1) series are precursor
GSL that give rise to well-known tumour-associated carbohydrate
antigens, such as Forssman antigen (Hakomori et al, 1977;
Taniguchi et al, 1981) and Globo H (Gilewski et al, 2001; Chang
et al, 2008; Wang et al, 2008). High levels of Pk (Gala1-4Galb1-
4Glcb1-1Ceramide; Gb3, CD77), P (GalNAcb1-3Gala1-4Galb1-
4Glcb1-1Ceramide; Gb4) and Globo H were described in the past
(Wenk et al, 1994).
As shown previously, naturally occurring AGA to P1 have the
potential to be used diagnostically in plasma of ovarian cancer
patients. However, it remains unknown whether P1-bearing GSL
are present on ovarian cancer cells and whether naturally occurring
anti-P1 antibodies to chemically synthesised carbohydrates in
glycan-based immunoassays bind to these GSL antigens. To our
knowledge, no published reports regarding the role of P1 in
malignant transformation, particularly in ovarian cancer, are
available, and the molecular mechanisms underlying GSL expres-
sion on the cell surface, as well as its function, have yet to be
elucidated. Therefore, this study aims (A) to determine the
responsible naturally occurring AGA immunoglobulin class
discriminating cancer from normal; (B) to determine whether
the level of these antibodies are predictive of patient outcome; (C)
to investigate whether the related P1 glycan epitopes are present on
cells isolated from ovarian cancer tissues as well as on ovarian
cancer cell lines; (D) to compare the AGA profiles in ascites and
matched plasma; (E) to compare monoclonal anti-P1 antibodies
produced in humans and affinity purified anti-P1 antibodies
isolated from ascites; and finally (F) to investigate the functional
role of the P1 antigen in ovarian cancer.
MATERIALS AND METHODS
Biospecimens. Two independent patient cohorts from two
different continents were used for the experiments: (A) matched
plasma and ascites from 11 serous FIGO stage III/IV cancer
patients from the previously described Swiss Discovery Cohort
(Jacob et al, 2012); (B) plasma from 155 Australian samples
(Australian Validation Cohort) comprising healthy controls,
borderline tumour and ovarian cancer patients. The Australian
Validation Cohort was split into: (1) borderline tumours and
adenocarcinomas of the ovary, tube and peritoneum (‘tumour
group’), and (2) healthy control women (‘control group’). Patients
were either admitted with an adnexal mass to the Gynaecological
Cancer Centre of the Royal Hospital for Women, Randwick,
Australia or were seen as outpatients to the Hereditary Cancer
Centre of The Prince of Wales Hospital, Randwick, Australia. All
patients were prospectively included after giving informed consent
in accordance with ethical regulations (Hunter Area Research
Ethics 04/04/07/3.04; South Eastern Sydney Illawarra HREC/
AURED Ref:08/09/17/3.02). The processing of blood plasma
samples was performed constantly on ice within 3 h after collection
as previously described (Jacob et al, 2011a, 2012). All clinico-
pathological data (Supplementary Table S1) such as FIGO stage
and grade were incorporated in a specifically designed in-house
database (‘PEROV’), which was developed using Microsoft Access
(Microsoft Corporation, Redmond, WA, USA). Diagnosis and
histopathological features were independently re-evaluated by a
pathologist specialised in gynaecological oncology (JS). Blood
samples were stored in aliquots at  80 1C.
Glycan-based immunoassays (printed glycan array, suspension
array and ELISA). The printed glycan array was performed as
previously described (Huflejt et al, 2009; Bovin et al, 2012; Jacob
et al, 2012). AGA were detected by ImmunoPure goat anti-human
IgAþ IgGþ IgM conjugated to long chain biotin (1 : 100, ‘Combo’,
Pierce, Rockford, IL, USA). To detect the immunoglobulin class,
developed printed glycan array slides were individually incubated
with 1 : 50-diluted biotin-conjugated goat anti-human IgA, IgG or
IgM (ZYMED Laboratories, Invitrogen, Carlsbad, CA, USA). The
coupling procedures for end-biotinylated glycopolymers and
antibody binding were described before (Pochechueva et al,
2011a, b). Experimental protocol was performed as described
previously (Pochechueva et al, 2011b). Exceptions were made with
respect to the use of goat anti-human IgG-R-PE or IgM-R-PE
secondary antibodies (Southern Biotech Ass. Inc., Birmingham,
AL, USA). ELISA was performed as described previously
(Pochechueva et al, 2011b).
Extraction and identification of GSLs from cancer tissue
samples and IGROV1 cell line. Fresh primary tissue samples
(B100mg) from a serous ovarian cancer and an endometrioid
peritoneal cancer patient were collected to analyse glycolipids by
negative ion electrospray ionisation mass spectrometry (LC-ESI-
MS/MS). Detailed analysis of the procedure is described in
Supplementary Information.
Affinity purification of anti-P1 antibodies. Ascites fluid was
collected from a late-stage serous ovarian cancer patient during
primary surgery. The ascites was processed by centrifugation at
4 1C, 3000 g for 15min. Supernatant was aliquoted and kept frozen
at  80 1C. Thawed ascites (50ml) was filtered through a 0.22-mm
filter (Millipore, Billerica, MA, USA) and diluted three times in
PBS (pH 7.4). Glycan-polyacrylamide-Sepharose stored in 20%
(v/v) ethanol was washed with 10 volumes 20% ethanol,
20 volumes milliQ water and equilibrated with 10 volumes of PBS.
Preprocessed ascites affinity purified against Gala1-4Galb1-
4GlcNAcb-polyacrylamide-Sepharose (P1-PAA-Seph; 10ml). A
constant flow rate of 1mlmin 1 was controlled by the use of an
auxiliary pump (Model EP-1 Econo Pump, Bio-Rad, Hercules, CA,
USA). Protein content and buffer composition was recorded by UV
at 280 nm and conductivity, respectively (BioLogic DuoFlow
Workstation, Bio-Rad). The column was washed with PBS
containing 0.05% (v/v) Tween 20, unplugged and stored overnight
at 4 1C. The next day, the column was inserted back into the
chromatography system and washed until no protein was detected
anymore. Bound anti-P1 antibodies were eluted using 0.2 M TrisOH
(pH 10.2) and neutralised by 2.0 M Glycine HCl (pH 2.5). Eluted
anti-P1 antibodies were concentrated using the Amicon Ultra-0.5
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centrifugal filter (Millipore), and their concentration was deter-
mined using spectrophotometrically at 280 nm.
Flow cytometry. GSL expression on the cell surface membranes
was analysed by flow cytometry (CyAn ADP Analyzer, Beckman
Coulter, Nyon, CH, USA) prior to antibody labelling. Unconju-
gated antibodies included anti-P1 human IgM (clone P3NIL100;
Immucor Gamma, Ro¨dermark, Germany), anti-P1 murine mono-
clonal IgM (clone OSK17; Immucor Gamma) and anti-Gb3
monoclonal IgG2b (CD77, Pk) (clone BGR23; Seikagaku Biobusi-
ness Corporation, Tokyo, Japan). Biotin-conjugated antibodies
included anti-human mouse IgM (BD Bioscience, Basel, Switzer-
land), rat anti-mouse IgM and rat anti-mouse IgG2b (BD
Bioscience). Streptavidin conjugated to FITC (BD Bioscience)
was used for fluorescence detection. Dead and apoptotic cells were
separated from live cells using propidium iodide (BD Bioscience).
Matching isotype monoclonal antibodies conjugated to FITC were
used as controls (BD Bioscience). All investigated cell lines were
gated individually to exclude debris, followed by single cell gating
to remove dead cells and doublets. Data acquisition was performed
using Summit v4.3 (CyAn ADP Analyzer, Beckman Coulter). Data
analysis was performed using FlowJo v9 (Tree Star Inc., Ashland,
OR, USA).
FACS sorting. IGROV1 cells were grown to 80% confluence,
washed twice in PBS and harvested using non-enzymatic cell
dissociation buffer (Sigma Aldrich, Buchs, Switzerland). Cells were
then washed in PBS containing 1% FCS and resuspended to 106
cellsml 1. Cell suspension (100 ml) was stained with human anti-
P1 IgM (BD Bioscience) as mentioned above and run on a BD
FACS Vantage SE DiVa Cell Sorter (BD Bioscience). IGROV1 cell
line was sorted using 490% and o10% fluorescence signal
intensity for P1-positive cells to receive P1-high and P1-low
fractions, respectively.
Flow cytometry-based inhibition assay. Monoclonal human IgM
antibody directed to P1 (Immucor Gamma, Ro¨dermark) was
preincubated either with Sepharose-P1-PAA or Sepharose-P
k-PAA
(Lectinity Holdings, Moscow, Russia) in different amounts ranging
from 0.015 mmol to 0.06 mmol for 60min at RT. The supernatant
was further processed as described in the flow cytometry section.
Colorimetric cell migration assay. Sub-confluent tumour cells
were ‘starved’ from serum by incubation in serum-free media for
24 h, before harvesting using a non-enzymatic cell dissociation
buffer (Sigma Aldrich, Buchs, Switzerland), washed twice and
resuspended in serum-free media containing 5% (w/v) BSA.
Tumour cells (7.5 105 in 300 ml) were loaded into cell culture
inserts containing a polyethylene terephthalate membrane with
8-micron pores (Millipore). The inserts were assembled into
24-well plates with each well containing 700 ml of media with 10%
supplemented with fetal calf serum, which was used as chemoat-
tractant. After incubation for 18 h at 37 1C, the media in the
interior of the insert was removed, and the entire insert was
immersed in 400 ml of 0.2% crystal violet/10% ethanol for 20min.
The insert was washed several times in water, and the non-
migrated cells in the interior of the insert were removed using a
cotton-tip swab. After air-drying, five random areas of the inserts
showing the migrated cells were photographed, and cell counts
were performed. Colorimetric cell migration assay was performed
three times.
In addition, parental IGROV1 cells were preincubated with 1%
(w/v) BSA in PBS, the corresponding isotype control (ChromPure
human IgM, Jackson ImmunoResearch Laboratories, Inc., MILAN
Analytica AG, Rheinfelden, Switzerland) and human anti-P1 IgM
(clone P3NIL100), both antibodies in a final concentration of
500 mgml 1). After 1 h incubation, cells were processed according
to previously described cell migration protocol.
MTT assay. Cultures were incubated with 500 mgml 1 (final
concentration) MTT dye (Sigma-Aldrich, Buchs, Switzerland) in
PBS for 3 h, followed by removal of the medium and dissolution of
the violet crystals in 200 ml of DMSO. The optical density
(absorbance at 540 nm) was measured with a SynergyH1 Hybrid
Reader (Biotek, Luzern, Switzerland). The data are given as
absorbance at 540 nm, representing cell viability as a function of
araC concentration. Each experiment was performed indepen-
dently twice from multiple cultures.
Real-time cell migration analysis (xCELLigence). Real-time cell
analysis (RTCA; xCELLigence System, Roche Diagnostics GmbH,
Mannheim, Germany) was used to investigate cell migration in
P1-low and -high serous ovarian cancer IGROV1 cells in a label-
free environment (Solly et al, 2004; Ke et al, 2011). Migration
was examined on 16-transwell plates (Roche Diagnostics GmbH)
with microelectrodes attached to the underside bottom of the
membrane for impedance-based detection of the migrated cells.
Prior to each experiment, cells were deprived of FCS over a period
of 24 h. Initially, 160 ml ‘chemoattractant’ media (RPMI 1640
containing 10% FCS) and 50 ml RPMI 1640 containing 1% FCS
was added to the lower and upper chambers, respectively. Sterile
PBS was loaded into the evaporation trophs. CIM-16 plates were
further prepared according to the manufacture’s protocol. Back-
ground signals generated by the cell-free media were recorded.
Cells were harvested using trypsin, counted and re-suspended in an
appropriate volume of RPMI 1640 containing 1% FCS. Cells
(100 000 cells per 100 ml medium) were seeded onto the upper
chamber of the CIM-16 plate and allowed to settle onto the
membrane. Cell-free media was used as negative control. Each
experiment was performed two times in duplicates. The pro-
grammed signal detection for quantification of the cell index was
measured every 15min over a period of 30 h. In an independent
migration assay, 5mM of 1-beta-D-arabinofuranosylcytosine (araC;
Sigma-Aldrich), a DNA polymerase inhibitor, was added to avoid
possible effects on migration caused by cell proliferation.
Statistical analysis. Detailed statistical procedure applied is
described in Supplementary Information.
RESULTS
IgM antibodies in plasma against P1 trisaccharide are reduced in
patients with tubal, peritoneal and ovarian cancer. In our
previous study, the use of three glycan-based immunoassays
(printed glycan array, ELISA and suspension array), detecting IgM,
IgG and IgA together, revealed significant AGA interactions with
the members of the P blood group system (Pochechueva et al,
2011a, b; Jacob et al, 2012). Overall, less AGA to P1 trisaccharide
(printed glycan array, ELISA and suspension array) and Pk
(printed glycan array) were observed in the plasma of the cancer
patient group compared with the control group (Pochechueva et al,
2011b; Jacob et al, 2012).
In this study, we investigated the levels of IgM and IgG AGA in
the plasma of an independent Australian Validation Cohort
(n¼ 155). The cohort consisted of a ‘benign’ control group
(healthy controls and benign gynaecological conditions; n¼ 81)
and a ‘tumour’ group (ovarian borderline tumours, ovarian, tubal
and peritoneal cancers; n¼ 74) (Supplementary Table S1). Based
on suspension array data, AGA to the P1 trisaccharide belonged
mainly to the IgM class (median, IQR; 9.948log(MFI), 9.351–
10.090log(MFI)) in all the tested samples. Significantly lower IgM
anti-P1 antibody levels were observed in the blood plasma samples
of the tumour as compared with the control group (P¼ 0.0002)
(Figure 1A). The tumour group revealed 15/74 (20.3%) samples
having lower AGA levels compared with the lowest control group
sample. Logistic regression did not reveal any relationship between
P1 antigen in ovarian cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.455 3
clinicopathological parameters and anti-P1 IgM antibody signatures
in the tumour group. In contrast to IgM, generally lower IgG
antibody levels (median, IQR; 7.35log(MFI), 6.726–7.858log(MFI))
were observed. Both the control and tumour groups were similar in
IgG AGA levels, with no significant difference in between both the
groups (P¼ 0.7248, Figure 1A). We have compared various clinical
parameters recorded along with collection of plasma samples for
each patient. Statistical evaluation revealed a significant discrimina-
tion in FIGO stage of the non-mucinous cancer of ovary, tube and
peritoneum group (FIGO Stage, non-mucinous cancer of the ovary,
tube and peritoneum I/II vs III/IV, P¼ 0.01773, t-test). The
remaining investigated clinical parameters were not significantly
different in their anti-P1 IgM antibody levels mentioning Grade (G1
vs G2/3, P¼ 0.2883; t-test) or tumour origin (ovary vs tube vs
peritoneum, P¼ 0.322; ANOVA). An increasing age has previously
been demonstrated to be associated with reduction of AGA in a
cohort of 48 control plasma samples using glycopeptide arrays
(Oyelaran et al, 2009). To investigate the influence of age on anti-P1
antibodies (IgG and IgM), we have applied Pearson’s correlation to
suspension array data and found a moderate negative correlation
(rho¼  0.33, Po0.01) in the entire cohort (mean age 56.4 (28–87)
years). However, in contrast to the control group that showed a
moderate negative correlation (rho¼  0.37, Po0.01), there was no
correlation between age and anti-P1 IgM levels in the tumour group
(rho¼  0.18, P¼ 0.123). This demonstrates that the reduction of
anti-P1 IgM is independent of age in the tumour group and further
indicates an association of these lowered IgM levels with the disease.
In contrast, we observed no correlation between age and anti-P1 IgG
levels in the control and tumour groups (Supplementary Figure S1).
With regards to the risk of cancer recurrence (relapse-free survival),
we observed that women with low IgM AGA levels to P1 (lower than
median fluorescence intensity, n¼ 33) were associated with a
slightly higher risk (P¼ 0.055) of having an earlier recurrence than
patients (n¼ 25) with higher levels of IgM anti-P1 antibodies
(hazard rate ratio 2.328, 95% CI 0.96–5.64) (Figure 1B). The disease-
free survival analysis did not reveal any significant effect (P¼ 0.605).
Identification of P blood group-related GSL in cancer tissues.
GSLs were extracted from fresh collected cancer tissues, and the
glycans released from the glycolipids in the form of alditols
(see ‘Materials and methods’) were analysed in the negative ion
mode using LC-ESI-MS/MS to identify P blood group-related
GSLs (Figure 2). The MS2 spectra contained adequate information
to facilitate the structural assignment of the glycans based
on the fragment ions arising from various glycosidic and cross-
ring cleavages, which were described previously (Domon and
Costello, 1988).
The base peak chromatograms of the glycan alditols released
from the GSLs extracted from serous ovarian (Figure 2A (a)) and
peritoneal (Figure 2B (a)) cancer tissue showed several compo-
nents. Globotriaosylceramide (Gb3, Pk) was detected as [M-H] 1
m/z 505.31 at low intensities, and the extracted ion chromato-
gram (EIC) showed it eluting at 15.4min (Figures 2A b(i) and B
b(i)). The MS2 spectra of the precursor ion at m/z 505.31
(Figure 2C (i)) showed prominent B- and C-type fragment ions (B1
at m/z 161.11 , C1 at m/z 179.2
1 and C2 at m/z 341.1
1 )
corresponding to a (Hex)3 or Gal-Gal-Glc sequence of Pk.
Characteristic cross ring fragment ions corresponding to 2,4A2 at
m/z 221.21 and 0,2A2 at m/z 281.0
1 were also present in the
spectrum, thereby confirming the presence of the 4-linked terminal
Gal to the (Gal-Glc) disaccharide (Karlsson et al, 2010). A similar
study indicated the absence of 0,2A2 fragment ion in the MS
2
spectrum of isoglobotriosylceramide (Gala1-3Galb1-4Glcb1)
(Karlsson et al, 2010) while previous reports have also noted that
this characteristic cross ring cleavage was useful in distinguishing
between Type 1 (Galb1-3GlcNAc) and Type 2 (Galb1-4GlcNAc)
chains commonly found in mucins (Chai et al, 2001; Robbe et al,
2004; Everest-Dass et al, 2012).
Globotetraosylceramide (P antigen, Gb4) was detected at [M-H] 1 -
m/z 708.31 and the EIC showed it to elute at 17.0min (Figures
2A c(ii) and B c(ii)). Despite appearing at low intensities, the MS2
spectra of the precursor ion at m/z 708.31 (Figure 2C (ii)) was
indicated by the B- and C-type fragment ions (B1 at m/z 202.0
1 ,
B3 at m/z 526.0
1 , C1 at m/z 220.0
1 and C2 at m/z 382.1
1 ),
which corresponded to the tetrasaccharide sequence, HexNA-
c1Hex3 or GalNAc-Gal-Gal-Glc of the P antigen. Several Y-ion
fragments seen from the reducing-end were also identified at m/z
343.21 (Y2) and m/z 505.2
1 (Y3) while the diagnostic cross ring
cleavages corresponding to 2,4A3 at m/z 424.1
1 and 0,2A3–H2O at
m/z 467.11 further confirmed the presence of 4-linked Gal to the
internal Galb1-4Glcb1 of the Gb4 tetrasaccharide.
The pentasaccharide P1, HexNAc1Hex4 or Gal-Gal-GlcNAc-
Gal-Glc, was detected at [M-H] 1 m/z 870.31 at 18.0min in
both tissue samples (Figures 2A d(iii) and B d(iii)). The glycosidic
fragment ions occurring at m/z 305.11 (B2–H2O ion) and m/z
341.01 (C2 ion) indicated the presence of the terminal Gal-Gal
epitope while the Y-type fragment ions at m/z 546.21 (Y3 ion)
and a prominent m/z 708.21 (Y4 ion) corresponded to the loss of
the Gal-Gal epitope and terminal Gal, respectively, from the
precursor ion, [M-H] 1 m/z 870.31 (Figure 2C (iii)). Besides
that, the prominent 2,4x4 fragment ion observed at m/z 648.3
1 in
the MS2 spectra was also characteristic of the terminal Gal residue
linked via a 4-linkage to the Gal-GlcNAc-Gal-Glc tetrasaccharide.
The cross ring cleavage at 0,2A3–H2O at m/z 425.1
1 and the
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Figure 1. Significantly lower levels of anti-P1 IgM in cancer patients in the Australian validation cohort (n¼ 155). (A) Box-and-whisker plots
showing distribution of AGA levels of IgM and IgG to covalently attached P1 trisaccharide using suspension array. Decreased AGA levels in cancer
patients were observed for IgM. (B) Kaplan–Meier curve on relapse-free survival showing that patients with low antibody levels (n¼33; lower than
median fluorescence signal) have slightly earlier relapse (P¼ 0.055) than those with high antibody levels (n¼25, higher than median fluorescence
signal).
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absence of the 0,2A4 at m/z 646.1
1 further demonstrates the
4-substitution of the GlcNAc residue and the 3-substitution of the
internal Gal and thus tentatively identified this compound as
Gala1–4Galb1-4GlcNAcb1–3Galb1-4Glc, the P1 antigen. The
three P blood group antigens were thus shown to be expressed
on the GSL of serous ovarian and peritoneal cancer tissues. There
was insufficient tubal cancer tissue sample to identify the presence
of these antigens.
P1 is expressed on IGROV1 cell surface. As IgMs were raised
against the P1 antigen in plasma from all types of ovarian cancer
patients, and the P1 (P
k and P) antigens were found to be expressed
on the GSL extracted from the cancer tissue of these patients, we
established an experimental cell culture model for the investigation
into the functional role of P1. Our panel of immortal cell lines,
including human ovarian surface epithelial cells (HOSE6-3 and
HOSE17-1) and various ovarian cancer cell lines (n¼ 6), were
profiled for P1 and P
k expression using flow cytometry (Figure 2D).
Serous ovarian cancer cell line IGROV1 was heterogenic for P1
expression (mean 34.1% ranging from 22.8% to 52.8%) based on
human anti-P1 IgM (clone P3NIL100) antibody. The second
antibody used in this study, monoclonal murine anti-P1 IgM (clone
OSK17), confirmed P1 expression on IGROV1 (mean 22.3%
ranging from 22.0% to 33.6%). IGROV1 cells were also positive for
Pk (mean 33.6% ranging from 12.0% to 54.0%). The normal
control cell line HOSE6-3 was negative for both P1 and P
k as were
the remaining ovarian cancer cell lines (n¼ 5).
To verify the presence of P1 on IGROV1 cell line, we isolated
GSLs from this cell line and analysed the released glycan alditols
using negative ion mode LC-ESI-MS/MS. The P1 pentasaccharide
at m/z 870.31 was shown to elute at 20.3min, and the MS2
spectra consisted of B2 (m/z 323.1
1 ), Y3 (m/z 546.3
1 -) and Y4
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Figure 2. P1 is expressed on cancer tissue cells. (A, B) Base peak chromatograms shown for serous ovarian cancer (A (a)) and endometrioid
peritoneal cancer tissue (B (a)). Selected mass peaks (red arrow) corresponding to the composition of the Pk trisaccharide (Hex3) (A and B b(i); m/z
505.31 ), P tetrasaccharide (Hex3HexNAc1) (A and B c (ii); m/z 708.3
1 ), and P1 pentasaccharide (Hex4HexNAc1) (A and B d(iii); m/z 870.3
1 ) are
represented as an extracted ion chromatogram (EIC). (C) MS2 spectrum of Pk trisaccharide (Gala1-4Galb1-4Glcb1) (i), P tetrasaccharide (GalNAcb1-
3Gala1-4Galb1-4Glcb1) (ii) and P1 pentasaccharide (Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb1) (iii). (D) Representative flow cytometry results
shown as contour plots with outliers demonstrate P1 and P
k negative cell lines HOSE6-3 and SKOV3. IGROV1 was detected positive with IgMs for
both P1 and P
k. Representative contour plots showing P1 and P
k expression (FITC; ordinate) and forward scatter (FSC; abscissa). Given percentage
corresponds to P1/P
k-positive cells.
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(m/z 708.31 ) fragment ions, which corresponded to the Gal-Gal-
GlcNAc-Gal-Glc sequence. The terminal Gala1–4Gal linkage was
also determined by the cross ring fragment ion at 2,4x4 fragment
ion observed at m/z 648.31 (Supplementary Figure S2).
Monoclonal anti-P1 IgM bind IGROV1 cells. Both P1 and P
k
share terminal disaccharide structure of composition Gala1–
4Galb1–4Glc(NAc). The monoclonal antibody to P1 (clone
P3NIL100) was used in a flow cytometry-based inhibition assay.
Sepharose conjugated PAA-lactose, -N-acetyllactoseamine (Lac-
NAc), -P1 trisaccharide, -P
k was incubated with the monoclonal
antibody to P1 before immunostaining of IGROV1 cells to observe
the degree of inhibition of IgM antibody binding to the expressed
P1 on IGROV1 cell surface. In this experiment, repeated three
times, flow cytometry of 52.8% P1-positive IGROV1 cells revealed
complete inhibition of monoclonal anti-P1 antibody by preincu-
bating with 0.015 mmol P1 glycoabsorbents (0.04%). In contrast,
less reduction (28.3% by 0.06 mmol Pk) of bound anti-P1 antibodies
to IGROV1 cells was observed in case of Pk glycoabsorbent
(Figure 3). Anti-P1 antibodies were only slightly inhibited by
preincubation with glycoadsorbents Lactose (0.06 mmol; 46.8%)
and LacNAc (0.06 mmol, 44.8%). This clearly demonstrates that
IGROV1 cells express P1 on their cell surface, and monoclonal
antibody to P1 shows clearly higher affinity to P1 compared with
Pk. It also demonstrates specifically that galactose a1–4 link is
required for antibody binding and that lactose and LacNAc are not
primarily epitopes of P1.
Anti-glycan antibodies levels are similar in ascites and blood
plasma. To determine whether anti-tumour antibodies were
expressed in ascites as well as plasma of patients, we investigated
the presence and distribution of AGA in matched ascites and blood
plasma samples (n¼ 11 patients) for IgA, IgG and IgM together
and separately using the printed glycan array. This was also done
for epitope mapping of ascites-derived human anti-P1 antibodies.
We detected a broad spectrum of AGA in both plasma and
ascites (Figure 4). The fluorescence scan of the binding to the
immobilised glycans on the array showed high amplitude of AGA
in ascites of IgG, IgM and IgA in both 50 mM and 10 mM glycan-
printed arrays (Supplementary Figure S3). We observed the highest
median relative fluorescence signals in ascites (median, 32.75 104
RFU) and in plasma (43.33 104 RFU) for anti-glycan IgM
antibodies. Anti-glycan IgG antibodies showed lower interaction
with the glycans (ascites (8.11 104 RFU), plasma (9.80 104
RFU) as well as anti-glycan IgA (ascites (8.8 104 RFU),
plasma (10.4 104 RFU)). Different levels of AGA to P1
trisaccharide were detected in all the tested ascites and plasma
samples (Figure 4). Highest binding to P1 was observed for IgM
(ascites (18.1 104 RFU), plasma (14.3 104 RFU)) compared
with IgG and IgA.
Matched ascites and plasma AGA signals were not dependent
on the volume of patient’s ascites. Based on raw data sets of 50mM
printed glycan arrays, strong correlation between matched ascites
and blood plasma samples was observed (Figure 4): IgAþ IgGþ
IgM (CCC¼ 0.889), IgA (CCC¼ 0.888), IgG (CCC¼ 0.961), and
IgM (CCC¼ 0.950). Correlations were similar for 10 mM printed
glycans. This demonstrates that detected AGA levels were
independent of the volume of ascites.
Naturally occurring anti-P1 antibodies in ascites bind to cancer
cells expressing P1 on their cell surface. The results achieved
from the above experiments demonstrated that (A) anti-P1
antibodies detected by glycan-based immunoassays are reduced
in plasma of cancer patients, (B) P blood group-related glycans are
detectable in tissue samples of cancer patients, (C) IGROV1
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ovarian cancer cell line was found to express P1 on its cell surface
among all the tested cell lines and (D) profiled ascites contained
AGA to P1 trisaccharide. Therefore the following series of
experiments were aimed to investigate whether IgM antibodies
derived from ascites bind to IGROV1 and in particular to P1
presented on its cell surface in the same way as the plasma-derived
autoantibodies.
We investigated AGA to P1 trisaccharide from an ascites sample
of a late-stage serous ovarian cancer patient. The ascites fluid was
first applied to the IGROV1 cell line in a 1 : 3 dilution, in which
24.3% of cells were stained positive with ascites-derived IgM
antibodies (Figure 5A). Based on this result, we proceeded to
affinity purify antibodies bound specifically to P1 trisaccharide
conjugated to sepharose beads. Affinity-purified proteins yielded a
maximum amount of IgM of 24 mg after concentration. Detection
of purified anti-P1 antibodies of class IgM revealed binding to
P1-expressing IGROV1 (15.1%) (Figure 5A). In contrast, the
ovarian cancer cell line SKOV3, negative for P1 and P
k expression,
had a positive staining of only 0.29% using the purified IgM-P1
antibodies. This demonstrates for the first time that ascites-derived
AGA directed to P1 trisaccharide also bind to naturally expressed
P1 on cell surface of ovarian cancer cells. In the following ELISA
experiment on purified IgM-P1 antibodies (Figure 5B), higher
values for IgM (OD450 nm¼mean 3.23±s.d. 0.08) compared with
IgG (OD450 nm¼ 1.08±0.02) were observed.
Next, we investigated whether purified IgM-P1 antibodies bind
to glycan structures other than P1 (potential cross-reactivity).
ELISA to a limited number of glycoconjugates revealed in the case
of IgM specific binding to P1 trisaccharide, with cross-reactivity to
Gala1-3GalNAc and Gala1-4GlcNAc (Figure 5B). Suspension and
printed glycan array were additionally utilised to study the cross-
reactivity to broader range of glycan structures, other than P1. In
suspension array, the binding of ascites-derived anti-P1 antibodies
to P1, P
k, Ley and a-rhamnose was tested. No preferential binding
was observed comparing P1 and P
k (P1 4.11log(MFI); P
k
4.24log(MFI), IgM class). In contrast, Ley and a-rhamnose coupled
beads revealed only minor binding. In the printed glycan array
(Figure 5C), we applied a threshold of 5% to the highest median
fluorescence signal (19 443 RFU; Gala1–4Galb1–4Glc-sp3) to
eliminate potentially unspecific binding as described previously
(Huflejt et al, 2009). We identified that affinity-purified IgM-P1
antibodies bound to P blood group-related structures as the top 10
glycans (Supplementary Table S2). Most of the identified low-
affinity binding to glycan structures had substructures of the P1
antigen such as Galb1-4Glc(NAc) with 63.0% and Gala1-4Galb
with 22.2% binding reactivity (Supplementary Table S2). This
demonstrates that affinity-purified IgM-P1 antibodies preferen-
tially bound to both Pk and P1 trisaccharide.
P1 expression leads to elevated migration rate in ovarian cancer
cells. GSLs on the cell surface are described to have several
functions in cellular processes, such as pathogen recognition,
angiogenesis, cell motility and cell migration (Panjwani et al, 1995;
Todeschini et al, 2008; Hakomori, 2010). Migration is a common
feature in cancer cells, and therefore we investigated whether or
not the presence of P1 affects cell migration by using a flow
cytometry-based cell sorting of IGROV1 cells to separate P1-high-
from P1-low-expressing subpopulations. After further sub-cultiva-
tion, P1 expression in P1-low IGROV1 cells was determined by
murine monoclonal anti-P1 IgM (OSK17; 18%) or human anti-P1
IgM (P3NIL100; 33.3%). In contrast, P1-high-expressing IGROV1
cells were 50.0% and 66.1% positive for P1, respectively, for these
antibodies (Figure 6A).
Utilising these P1-sorted cell lines, we hypothesised that the
presence of P1 affects cell migration. Significantly higher migration
was detected in P1-high-expessing when compared with P1-low-
expressing IGROV1 cells after an 18 h incubation period
(P¼ 0.0006) (Figure 6B), as shown by colorimetric cell migration
assay. In addition to end-point migration assay, real-time and
label-free measurement of P1-sorted IGROV1 cells was performed
using the xCELLigence system. A number of 100 000 cells was
seeded into each well of the upper chamber, and migration through
the microporous membrane were recorded as cell index. IGROV1
cells with higher P1 were significantly faster after 20 h (P¼ 0.035)
than low P1 cells. Longer incubation periods resulted in no
difference between both subpopulations (30 h; P¼ 0.1337, 40 h;
P¼ 1; Figure 6C). To avoid the influence of potentially elevated
proliferation effects, 5mM cytosine arabinoside (araC) was added to
the cell culture (Supplementary Figure S4). In concordance with
results on the colorimetric cell migration assay and observations on
initial xCELLigence experiment, cells with elevated P1 displayed
high basal migratory activity as indicated by the increases in cell
index values, reflecting the number of migrating cells. In contrast,
P1-low-expressing cells failed to migrate under experimental
conditions. With regard to migratory kinetics, P1-high-expressing
cells migrated rapidly and demonstrated elevated (4.7-fold) cell
index of 0.3434±0.054 (mean±s.d.) as compared with P1-low-
expressing cells (0.0726±0.029; P¼ 0.004, CI 0.1–0.45). This
difference remained constant throughout the 40 h time course
experiment (20 h–3.6-fold (Po0.001, CI 0.32–0.66); 30 h–3.6-fold
(Po0.001, CI 0.40–0.75); 40 h–4.6-fold (Po0.001, CI 0.49–0.84);
Figure 6C). These findings demonstrate that ovarian cancer cells
expressing P1 on their cell surface migrate faster compared with
low-P1-expressing cells originated from the same parental cell line.
In order to confirm that P1 is involved in cell migration, we
performed the colorimetric cell migration assay with anti-P1 IgM-
pretreated IGROV1 cells. The results (Figure 6D) showed that the
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percentage of migrated cells was significantly lower (reduction by
64%; Po0.001) in cultures preincubated with the anti-P1 IgM
antibody. Pretreatment with the respective IgM isotype control did
not affect the migration of IGROV1 cells.
DISCUSSION
Unlike Pk, which has been extensively studied in the areas of
verotoxin-mediated cytotoxicity, human immunodeficiency virus
infection, immunology and epithelial carcinogenesis, there is,
to our knowledge, no published study of P1 and its potential
presence, immunogenicity and its functional role in oncogenesis.
Using glycan-based immunoassays, we have previously demon-
strated that naturally occurring AGA significantly distinguish
healthy controls from ovarian cancer patients (Pochechueva et al,
2011b; Jacob et al, 2012). The present study demonstrates that: (A)
an unknown subpopulation of cancer patients show reduced levels
of anti-P1 IgM antibodies in an extended and independent cohort
from another continent (Australian Validation Cohort), (B) Pk, P
and P1 carbohydrate antigens are detectable in cancer tissue as well
as on the cell surface of cultured ovarian cancer cells, (C) ascites
contains similar anti-glycan IgM-P1 antibody levels compared with
blood plasma independent of its volume at the primary diagnosis,
(D) naturally occurring AGA of IgM class derived from ascites of a
Control
0.88%
Bla
nk Glc Ma
n
Rh
a
6-O
-Su
-G
al
1-4
Glc
NA
c
Glc
NA
c1
-3G
aI
1-4
Glc
NA
c
6,6
-O
-Su
-G
al
1-4
Glc
NA
c
O
D 
at
 4
50
 n
m
0
1
2
3
4
IgM
IgG
FI
TC
 (P
1 
+
  
ce
lls
)
24.3% 15.1%
FSC
Anti-P1 IgMAscites IgM
Ga
l1
-3G
alN
Ac
Ga
l1
-4G
aI
1-4
Glc
NA
c
Ga
l1
-4G
lcN
Ac
Gal1–4Gal1–4GIc-sp3
Gal1–3GlcNAc-sp3
Gal1–4Gal1–4Glc-sp2
Gal1–4Gal1–4GlcNAc-sp2
Fuc1–4(Fuc1-2Gal1–3)
GlcNAc1–3Gal1–4Glc-sp4
Fuc1–4(Fuc1–2Gal1–3)GlcNAc-sp4
Gal1–4GlcNAc1–6
Gal1–4GlcNAc-sp2
GalNAc1–3Gal1–4Gal1–4Glc-sp3
R
FU
*1
0'
00
0;
 
10
 
M
 p
rin
t
2.0
1.5
1.0
0.5
0.0
2.0 2.51.51.00.50.0
RFU*10'000; 50 M print
Figure 5. Human ascites-derived affinity-purified anti-P1 antibodies bind to IGROV1 cells. (A) Flow cytometry-based contour plots demonstrate
the presence of IgM antibodies in ascites (1 : 3 diluted in PBS) bound to IGROV1 cells (ascites IgM, 24.3%) compared with unstained sample
(control). Affinity-purified anti-P1 IgM (1 : 20) bound to IGROV1 cells (15.1% of P1-positive cells). (B) Representative ELISA demonstrating the cross-
reactivity of affinity-purified anti-P1 antibodies of class IgM (dark grey) and IgG (light grey) to investigated glycans linked to PAA. (C) Printed glycan
array data (scatterplot for 50mM vs 10mM saccharide prints) showing cross-reactivity to glycans sharing related carbohydrate structures. Grey area
indicates unspecific binding of AGA as determined by 5% threshold. Inter-quartile range is shown for each glycan horizontally and vertically for
50mM and 10mM, respectively.
BRITISH JOURNAL OF CANCER P1 antigen in ovarian cancer
8 www.bjcancer.com |DOI:10.1038/bjc.2014.455
ovarian cancer patient bind to naturally expressed and chemically
synthesised P1 on glycan arrays, and (E) the presence of P1 on
ovarian cancer cultured IGROV1 cells leads to enhanced migration.
Our results demonstrate that the significantly lower anti-P1
antibody levels observed in cancer patients were primarily due to
the reduction of IgM but not IgG antibodies. This is in full
concordance with the literature on the IgM type anti-Thomsen
Friedenreich antibodies (Desai et al, 1995) and anti-Lewis C
antibodies in breast cancer (Bovin, 2013). A very recently
published work demonstrated significantly reduced human IgM
antibodies to another GSL (N-glycolylneuraminyl)-lactosylcera-
mide (NeuGcGM3) in non-small cell lung cancer patients
(Rodriguez-Zhurbenko et al, 2013). Therefore we can assume that
IgM class of naturally occurring AGA was able to discriminate
between cancer and healthy controls. Natural IgM antibodies
belong to the innate immune system and are primarily produced
by B1 or CD5þ cells (Boes, 2000; Martin and Kearney, 2001; Viau
and Zouali, 2005). As part of the natural immunity, the binding of
IgM to conserved carbohydrate structures acts as a first barrier to
all invasive particles (‘external’) and alterations on proteins and
lipids within an organism (‘internal’) (Vollmers and Brandlein,
2007). To date, several human monoclonal antibodies directed to
tumour-associated carbohydrate antigens have been isolated. For
instance, the monoclonal IgM antibody, SAM-6, specific for
cancerous tissue was first derived from a gastric cancer patient
(Pohle et al, 2004). Later, it was found that the receptor for SAM-6
is a tumour-specific O-linked carbohydrate epitope on GRP78, a
central regulator of endoplasmatic reticulum in protein folding
(Li and Lee, 2006). PAM-1, another monoclonal IgM antibody,
binds to a tumour-specific N-linked carbohydrate epitope, a
posttranslational modification on cysteine-rich fibroblast growth
factor receptor, CFR-1. This antibody also inhibited tumour
growth in vitro and in animal model systems by inducing apoptosis
(Brandlein et al, 2003, 2004a, b). Consistent with the findings of
Vollmers and colleagues regarding SAM-6 and PAM-1, our
observation based on hierarchical clustering indicates that AGA
preferentially bind to substructures of the glycan epitope (Jacob
et al, 2012). Besides that the decrease of AGA mainly of the IgM
class in gynaecological cancer patients (Jacob et al, 2012) also
points to an involvement of naturally occurring IgM autoantibo-
dies, which recognise GSL structures. We further propose that
Gala1-4Galb1-4Glc(NAc) (present in P, Pk and P1 antigens) are a
result of malignant transformation and could serve as an ‘internal’
epitope on GSLs that is recognised by naturally circulating anti-
glycan IgM antibodies.
The observation of lower levels of anti-P1 IgM compared with
anti-P1 IgG in cancer patients is very intriguing, and although
exploring the underlying mechanisms was beyond the scope of the
study, we speculate on a number of possibilities. The elevated
presence of corresponding antigens on cancer cells, in our case P1
GSL, may be bound by circulating anti-P1 IgM and therefore no
longer be freely floating in the plasma and ascites. Another
potential mechanism may be tumour-induced immune suppres-
sion. It is known that ovarian cancers employ a range of strategies,
such as secretion of immunosuppressive cytokines, to facilitate
their escape from immune destruction (Lavoue et al, 2013). It is
possible that this may lead to reduced antibody production against
cancer-associated antigens, for example, P1, conferring a survival
advantage to cancer cells. The antibody repertoire in cancer
patients would therefore be different. Another possible mechanism
is the occupation of anti-P1 IgMs by cancer cells (including
circulating tumour cells) by virtue of their surface expression of
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Figure 6. Elevated P1 expression results in increased migration rate. (A) FACS-sorted subpopulations of P1-low- and -high-expressing IGROV1
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the migrated cells (cell index) in bar graphs at the time points 0 h, 10 h, 20 h and 30h. Left bar graph shows RTCA experiment without araC, right
bar graph with araC as proliferation inhibitor. Representative figure out of two independent experiments. (D) Bar chart showing the inhibition of
cell migration of human IGROV1 cells incubated with anti-P1 IgM compared with corresponding incubation with IgM isotype control. Number of
migrated cells was normalised to control. Not significant (NS); *Po0.05, **Po0.01, ***Po0.001.
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P1, leading to a reduction in the amount of unbound antibody in
plasma and/or ascites. The formation of immune complexes
consisting of P1 antigen shed from cancer cells, and anti-P1 IgMs,
may further contribute to this reduction. A prominent example in
the literature for the formation of circulating immune complexes
consisting of Lewis x and antibodies has been shown in
Helicobacter pylori-infected human (Chmiela et al, 1998). With
regards to no change being observed in the anti-P1 IgG levels, we
expected differences preferentially in the case of IgM rather than of
IgG as glycan-based antigens are T-cell-independent antigens and
are recognised by the innate immune system.
Our mass spectrometry results demonstrated that these P1, P
k
and P antigens are expressed on ovarian and peritoneal cancer
tissues. The functional role of the GSL that carry these structures in
carcinogenesis is poorly understood, especially in the case of P1
and P. It was recently described that a monoclonal anti-Pk
antibody (E3E2) inhibited angiogenesis and tumour development
(Desselle et al, 2012). Enhanced expression of Pk has also been
shown to cause doxorubicin resistance in breast cancer cells (Gupta
et al, 2012). Cisplatin-resistant pleural mesothelioma cells were
shown to be sensitised to cisplatin by the addition of sub-toxic
concentrations of Verotoxin 1 (Johansson et al, 2010). In addition,
we also demonstrate that P1 and P
k antigens are also present on the
surface of the IGROV1 serous ovarian cancer cells. IGROV1 is,
therefore, to the best of our knowledge, the only immortal cell line
from several investigated that expresses P1. Using monoclonal
antibodies against P1, only minor cross-reactivity to other glycan
structures was observed in glycan-based immunoassays (not
shown). Furthermore, based on the flow cytometry inhibition
assay using IGROV1 cells as an investigative model, the specificity
of monoclonal antibodies to P1 as shown by the full saturation of
anti-P1 antibodies by inhibition with 0.06 mmol glycan on
sepharose beads indicates that IGROV1 expresses P1 on the cell
surface.
Serous pelvic masses commonly present with malignant ascites,
a plasma–protein-rich intraperitoneal exudate of up to several
litres. Several pathophysiological mechanisms are necessary for
malignant ascites occur: (a) decreased lymphatic ascites absorption,
(b) increased capillary permeability, (c) increased overall capillary
membrane-surface area available for filtration, and consequently
(d) an increased intraperitoneal oncotic pressure due to intraper-
itoneal protein concentration (Tamsma et al, 2001). Using the
printed glycan array, we observed an unexpectedly rich spectrum
of AGA with similar amounts in plasma and ascites. These findings
suggested that there is an equilibrium between both body fluids.
Early lymphatic obstruction is one of the first manifestations of an
inflammatory reaction (Feldman, 1975). As IgM has an important
role in inflammation with multivalent antigen binding due to its
pentameric structure and as the first immunoglobulin class
produced in a primary response to an antigen, lymphatic
obstruction may result in a rapid increase in IgM secreting plasma
cells. Natural circulating AGA have also been described in various
inflammatory conditions, including diabetes mellitus type 1
(Gillard et al, 1989), chronic inflammatory bowel and Crohn’s
disease (Malickova et al, 2006) and in patients with cancer (Young
et al, 1979; Springer, 1984; Springer et al, 1988; Desai et al, 1995).
We also investigated the expression of A4GALT P1- and P
k-
profiled cell lines. As seen in our study, A4GALT is overexpressed
in the P1- and P
k-positive ovarian cancer cell line IGROV1 (Jacob
et al, 2011b), suggesting that A4GALT is not only involved in Pk
but also in P1 synthesis in ovarian cancer cells. We propose that
A4GALT is involved in the progression of various ovarian and
peritoneal cancers; however, the molecular link between A4GALT
mRNA levels and P1 expression remains unknown. This is
consistent with suspension array results in which no tested clinical
parameters were shown to correlate with lower AGA levels to P1
trisaccharide. A recently identified single nucleotide polymorphism
(CT conversion) encoding an additional exon in the genomic
region of A4GALT (Thuresson et al, 2011) could probably explain
the presence of P1 in cancer cells. However, it is unclear whether
the overexpression of A4GALT is causative for the synthesis of P1
or Pk in profiled cancer cell lines. The invasive phenotype of colon
cells lacking Pk could be induced and inhibited by the transfection
of Gb3 synthase (A4GALT) or RNA interference, respectively
(Kovbasnjuk et al, 2005). Another immunohistochemistry-based
study showed that Pk expression was elevated in colorectal cancers
and their metastases; however, A4GALT mRNA levels, protein
expression or galactosyltransferase activity were not investigated
(Falguieres et al, 2008). The potential role of A4GALT in cancer
initiation or progression needs to be elucidated in future studies
with respect to all P blood group-related glycans.
For the first time, we also observed migration rate in P1-high-
expressing cells, and this was even more obvious when araC, a
proliferation inhibitor, was added to the cultures (Roy et al, 2006).
The addition of araC confirmed that the observed difference in
migration was indeed due to altered cell migration and not cell
proliferation. Our results suggest an involvement of P1 in cell
migration, but the underlying molecular mechanisms are unknown.
Finally, this study provides further evidence that P blood group-
related antigens have a role in carcinogenesis and those naturally
occurring anti-glycan IgM antibodies against them may have the
potential to discriminate ovarian cancer patients from healthy
individuals. If these surface antigens prove to be indeed tumour-
specific, they may become candidate molecular targets for potential
imaging tools for confocal fluorescence endoscopy and positron
emission tomography and as tools in targeted immunotherapy
(Janssen et al, 2006; Viel et al, 2008).
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